



Ad hoc announcement pursuant to Art. 53 LR

Newron Pharmaceuticals Annual General Meeting 2025: Chris Martin elected as new Chairman of the Board of Directors

Milan, Italy, April 23, 2025, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that its shareholders approved all motions on the agenda for the ordinary part of its 2025 Annual General Meeting (AGM), held today.

At the AGM, Dr. Chris Martin was elected as the new Chairman of the Board. The motions on the agenda for the extraordinary part of the meeting were not put to vote, due to the required quorum not being reached. In that context, Newron’s Board of Directors has extended the capital increase granted by its shareholders’ meeting on 27 March 2018, and executed by the Board of Directors on March 24, 2023, to March 31, 2028, to the extent it has not yet been subscribed (nominal EUR 701,124.80).

Ulrich Köstlin, outgoing Chairman of the Board of Directors of Newron, commented: *“We thank all our shareholders for their longstanding support. At the same time, I warmly welcome Chris Martin to Newron. I am delighted that an industry expert with his expertise and vision has agreed to serve as Chairman”.*

Chris Martin, newly elected Chairman of the Board of Directors of Newron, added: *“I would like to thank all Newron shareholders for their trust. I look forward to continuing to lead the Company, together with the Board of Directors, the management team and the employees, along the path that Ulrich has so conscientiously and judiciously laid out.”*

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system.

Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications.

Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea.

Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika.

For more information, please visit: www.newron.com

For more information, please contact:

Newron

Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com

Switzerland

Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe

Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA

Paul Sagan, LaVoieHealthScience; +1 617 865 0041, psagan@lavoiehealthscience.com